<DOC>
	<DOC>NCT00002217</DOC>
	<brief_summary>The purpose of this study is to test the effectiveness of Combivir plus abacavir plus 141W94 in patients who previously have used anti-HIV drugs.</brief_summary>
	<brief_title>A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs</brief_title>
	<detailed_description>In this open-label study antiretroviral-experienced patients receive Combivir (3TC/AZT tablet) plus 1592U89 (abacavir) and 141W94 twice daily for 48 weeks.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<criteria>Inclusion Criteria Patients must have: CD4 count greater than 50 cells/mm3. HIV RNA less than 50,000 copies/ml. No active AIDS (excluding CD4 count less than 200 cells/mm3). Ability to comply with dosing schedule and protocol evaluations. Prior Medication: Allowed: AZT or nonnucleoside reverse transcriptase inhibitors (NNRTIs). Exclusion Criteria Coexisting Condition: Patients with any of the following symptoms or conditions are excluded: Active AIDS (not excluding CD4 count less than 200). Malabsorption syndrome affecting drug absorption. Serious medical condition that would compromise safety of the patient. Concurrent Medication: Excluded: AZT or NNRTIs. More than 1 week treatment with any protease inhibitor. Enrollment in any other investigational drug protocol. Patients with the following prior conditions are excluded: History of clinically relevant pancreatitis or hepatitis within the past 6 months. Required: Antiretroviral therapy with either single or double reverse transcriptase inhibitors.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1999</verification_date>
	<keyword>Drug Therapy, Combination</keyword>
	<keyword>Patient Compliance</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>abacavir</keyword>
</DOC>